PDCD1 and hepatocellular carcinoma: Thus, DOX@3D-MPs efficiently boosted anti-PD-1 antibody therapy in multiple tumor models, including large subcutaneous H22 hepatoma tumor model, orthotopic 4T1 breast tumor and Panc02 pancreatic tumor models, and even in HCC patient-derived tumor tissues, generating strong antitumor immune memory to inhibit tumor recurrence.